246 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Not yet recruiting Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
Condition: Pineoblastoma
Interventions: Drug: Temozolomide;   Drug: Irinotecan;   Drug: Dasatinib;   Drug: Rapamycin
2 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
3 Active, not recruiting Combination Of Lapatinib With Carboplatin, Paclitaxel and Trastuzumab In Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: lapatinib;   Drug: carboplatin;   Drug: trastuzumab;   Drug: paclitaxel
4 Not yet recruiting A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: vadastuximab talirine
5 Recruiting Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma
Condition: Colorectal Cancer
Intervention: Drug: MITOMYCIN-C 40 mg
6 Completed Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Pirarubicin;   Drug: Docetaxel;   Drug: Cyclophosphamide
7 Not yet recruiting Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: Obinutuzumab;   Biological: Ublituximab;   Drug: TGR-1202;   Drug: Chlorambucil
8 Not yet recruiting IRX-2 Regimen in Patients With Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity
Condition: Squamous Cell Carcinoma of the Oral Cavity
Interventions: Biological: IRX-2;   Drug: Cyclophosphamide;   Drug: Indomethacin;   Dietary Supplement: Zinc-containing multivitamin;   Drug: Omeprazole
9 Recruiting Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer;   Metastatic Carcinoma
Interventions: Drug: temozolomide;   Radiation: prophylaxis cranial radiotherapy
10 Recruiting Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: CXCR4 Antagonist;   Procedure: Hematopoietic Stem Cell Transplantation
11 Not yet recruiting Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
12 Withdrawn Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Temozolomide;   Radiation: Radiation;   Drug: Sorafenib
13 Not yet recruiting High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
14 Recruiting Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions: Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: MPDL3280A;   Drug: Obinutuzumab;   Drug: Prednisone;   Drug: Vincristine
15 Not yet recruiting Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Colorectal Large Cell Neuroendocrine Carcinoma;   Esophageal Large Cell Neuroendocrine Carcinoma;   Gallbladder Large Cell Neuroendocrine Carcinoma;   Gastric Large Cell Neuroendocrine Carcinoma;   Pancreatic Large Cell Neuroendocrine Carcinoma;   Small Intestinal Large Cell Neuroendocrine Carcinoma
Interventions: Drug: Capecitabine;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
16 Recruiting Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone
17 Recruiting A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma (PTCL)
Intervention: Drug: Pralatrexate Injection
18 Recruiting Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B-cell Lymphoma Refractory;   Follicular B-cell Non-Hodgkin's Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Rituximab;   Drug: Bendamustine
19 Not yet recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Low dose FRα vaccine;   Drug: Cyclophosphamide;   Biological: High dose FRα vaccine
20 Recruiting Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, B-cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular, Grade 3b;   Follicular Lymphoma, Grade 3b
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years